A BILL 
To require the Secretary of Health and Human Services 
to maintain a list of the country of origin of all drugs 
marketed in the United States, to ban the use of Federal 
funds for the purchase of drugs manufactured in China, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Protecting Our Phar-
4
maceutical Supply Chain from China Act of 2020’’. 
5
03:53 Apr 18, 2020
H6482
2 
•HR 6482 IH
SEC. 2. COUNTRY OF ORIGIN OF DRUGS. 
1
(a) IN GENERAL.—Subchapter A of chapter V of the 
2
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351 
3
et seq.) is amended by adding at the end the following: 
4
‘‘SEC. 524B. REGISTRY OF DRUGS PRODUCED OUTSIDE THE 
5
UNITED STATES. 
6
‘‘(a) IN GENERAL.—The Secretary shall compile and 
7
maintain a list of all drugs approved under subsection (c) 
8
or (j) of section 505 of this Act or licensed under sub-
9
section (a) or (k) of section 351 of the Public Health Serv-
10
ice Act, and any active ingredients in such drugs, that— 
11
‘‘(1) are manufactured outside of the United 
12
States; and 
13
‘‘(2) are determined by the Secretary to be crit-
14
ical to the health and safety of consumers in the 
15
United States. 
16
‘‘(b) ADDITIONAL LIST.—In conjunction with the list 
17
described in subsection (a), the Secretary shall compile 
18
and maintain a list of drugs included on such list that 
19
are exclusively produced in, or use active or inactive ingre-
20
dients produced in, the People’s Republic of China. 
21
‘‘(c) REQUIREMENT.—The list described in sub-
22
section (a) shall, with respect to each drug included on 
23
the list, provide information about the drug’s supply chain, 
24
including each step in the supply chain that occurs prior 
25
to the drug’s importation into the United States.’’. 
26
03:53 Apr 18, 2020
H6482
3 
•HR 6482 IH
(b) FEDERAL HEALTH PROGRAM PURCHASE
OF 
1
DRUGS.— 
2
(1) IN GENERAL.—Notwithstanding any other 
3
provision of law, the Department of Health and 
4
Human Services, the Department of Veterans Af-
5
fairs, the Department of Defense, and any other 
6
Federal health care program (as defined in section 
7
1128B(f) of the Social Security Act (42 U.S.C. 
8
1320a–7b(b)), with respect to the purchase of a 
9
drug by such agency or program, the following shall 
10
apply: 
11
(A) By 2022, a purchaser of drugs de-
12
scribed in this subsection shall only purchase 
13
drugs that contain 60 percent or more of their 
14
active pharmaceutical ingredients manufactured 
15
in countries— 
16
(i) other than the People’s Republic of 
17
China; and 
18
(ii) that meet the Food and Drug Ad-
19
ministration’s health and safety standards. 
20
(B) By 2023, a purchaser of drugs de-
21
scribed in this subsection shall only purchase 
22
drugs that contain 100 percent of their active 
23
pharmaceutical ingredients manufactured in 
24
countries— 
25
03:53 Apr 18, 2020
H6482
4 
•HR 6482 IH
(i) other than the People’s Republic of 
1
China; and 
2
(ii) that meet the Food and Drug Ad-
3
ministration’s health and safety standards. 
4
(2) WAIVERS.—The Secretary of Health and 
5
Human Services may issue waivers of the require-
6
ments under paragraph (1) for any agency or pro-
7
gram that is unable to meet such requirements and 
8
demonstrates a need for the waiver. No waiver may 
9
be issued under this paragraph for drugs that are 
10
purchased on or after January 1, 2025. 
11
(c) LABELING REQUIREMENT.—Section 502 of the 
12
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) 
13
is amended by adding at the end the following: 
14
‘‘(ee) If it is a drug and its labeling does not specify 
15
the country of origin of each active ingredient contained 
16
in the drug.’’. 
17
SEC. 3. TEMPORARY 100 PERCENT EXPENSING FOR PHAR-
18
MACEUTICAL AND MEDICAL DEVICE MANU-
19
FACTURING PROPERTY. 
20
(a) IN GENERAL.—For purposes of section 168(k) of 
21
the Internal Revenue Code of 1986, in the case of any 
22
qualified pharmaceutical and medical device manufac-
23
turing property which is placed in service after December 
24
31, 2019, and before January 1, 2026— 
25
03:53 Apr 18, 2020
H6482
5 
•HR 6482 IH
(1) such property shall be treated as qualified 
1
property (within the meaning of such section); 
2
(2) the applicable percentage otherwise deter-
3
mined under section 168(k)(6) of such Code with re-
4
spect to such property shall be 100 percent; and 
5
(3) paragraph (8) of such section shall not 
6
apply. 
7
(b) QUALIFIED PHARMACEUTICAL
AND MEDICAL 
8
DEVICE MANUFACTURING PROPERTY.—For purposes of 
9
this section, the term ‘‘qualified pharmaceutical and med-
10
ical device manufacturing property’’ means any tangible 
11
property placed in service in the United States as part 
12
of the construction or expansion of property for the manu-
13
facture of drugs (as defined in section 201(g) of the Fed-
14
eral Food, Drug, and Cosmetic Act (21 U.S.C. 321(g)) 
15
or medical devices (as defined in section 201(h) of such 
16
Act (21 U.S.C. 321(h)). 
17
(c) TERMINATION.—This section shall not apply to 
18
any property placed in service after December 31, 2025. 
19
SEC. 4. RULE OF CONSTRUCTION. 
20
Nothing in this Act shall be construed to divert the 
21
resources of the Food and Drug Administration from re-
22
sponding to the COVID-19 public health emergency. 
23
Æ 
03:53 Apr 18, 2020
H6482
